Innate Pharma (IPH.PA) Stock Price
Innate Pharma Price
Revenue at Innate Pharma has contracted by 4.1% per year over the past 19 years to 2.79 M EUR. For Innate Pharma, the net margin of -1,764.5% is down versus -436.0% a few years ago. The consensus 12-month price target for Innate Pharma is 4.49 EUR, about 240.0% above where the stock trades today. Of 10 analysts, 7 rate the stock a buy — an overall Buy consensus.
Innate Pharma stock price
Innate Pharma business model & stock analysis
Frequently asked questions about Innate Pharma
The business model of Innate Pharma SA is centered around the development and commercialization of innovative immunotherapies for the treatment of cancer and inflammatory diseases. Innate Pharma combines cutting-edge expertise in immunology with advanced technology platforms to discover and develop first-in-class antibodies targeting receptors and pathways controlling the activation and regulation of the immune system. By leveraging its scientific know-how and strategic partnerships, Innate Pharma aims to bring novel immunotherapies to patients, addressing unmet medical needs and potentially improving outcomes. Innate Pharma SA focuses on research, development, and collaboration to advance its pipeline and ultimately deliver breakthrough therapies.
Innate Pharma SA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Innate Pharma SA in the market include larger biopharmaceutical companies such as Bristol-Myers Squibb, Amgen, and Novartis. They operate in the same industry and compete for similar market segments and resources. These competitors pose a challenge to Innate Pharma SA as they have strong financial capabilities, established market presence, and a diverse product pipeline. Innate Pharma SA, however, differentiates itself through its innovative drug discovery platforms and focuses on developing immune-based therapies for the treatment of cancer and inflammatory diseases.
Innate Pharma SA is a biotechnology company based in Marseille, France. Founded in 1999, the company focuses on developing innovative immunotherapies for the treatment of cancer and inflammatory diseases. Innate Pharma is committed to harnessing the power of the innate immune system to fight against diseases. The company has a strong track record in the field of antibody-based therapies and has established strategic partnerships with leading pharmaceutical companies for the development and commercialization of its products. Innate Pharma SA has a dedicated team of scientists and researchers working towards advancing the understanding and application of immunotherapies for improved patient outcomes.
Innate Pharma SA has achieved significant milestones in its journey. The company has successfully developed innovative therapies in the field of immuno-oncology. Innate Pharma SA collaborated with leading pharmaceutical companies, such as AstraZeneca and Novo Nordisk, for the clinical development of its products. Additionally, the company has made remarkable progress in advancing its pipeline, including the advancement of its lead product candidate, monalizumab, into clinical trials for various cancer indications. Innate Pharma SA has also secured a strong intellectual property portfolio to protect its cutting-edge technologies and remains committed to revolutionizing the treatment of cancer and other diseases.
Innate Pharma SA is primarily present in various countries and regions around the world. The company has a global presence with a focus on key markets including the United States, Europe, and Asia. Innate Pharma SA has established its presence in the United States through its subsidiary, Innate Pharma US Inc., which is located in Rockville, Maryland. In Europe, the company has a strong presence in France, its home country, as well as in other European countries. Additionally, Innate Pharma SA has been expanding its reach in the Asian market, particularly in Japan and China.
Innate Pharma SA represents values of innovation, collaboration, and patient focus. The company is committed to advancing the field of immuno-oncology through its pioneering research and development efforts. Innate Pharma SA believes in working closely with partners and leveraging their expertise to accelerate the discovery of new therapeutic solutions. With a strong focus on addressing unmet medical needs, Innate Pharma SA aims to improve patient outcomes and make a difference in the fight against cancer. By combining cutting-edge science with a patient-centric approach, the company strives to bring innovative and effective treatments to market.
Analysts currently set an average price target of 4.44 EUR for the Innate Pharma stock (median: 4.49 EUR), implying +236.3 % versus the latest price. The consensus is based on 10 analyst ratings.
8 analysts currently rate the Innate Pharma stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Innate Pharma to generate revenue of 49.38 M EUR and earnings per share of -0.13 EUR.
The Innate Pharma share (IPH.PA) is listed on 7 stock exchanges, including: London (0EVI.L), Frankfurt (IDD.F), München (IDD.MU), Düsseldorf (IDD.DU), Paris (IPH.PA).
Innate Pharma SA is a biopharmaceutical company specializing in the research and development of immunoncology therapies. The company is headquartered in Marseille, France, with subsidiaries in the United States and Switzerland. Innate Pharma SA's business model focuses on the identification and development of novel target molecules and compounds with therapeutic potential in cancer and other immune system diseases. The company has an extensive portfolio of proprietary technologies and platforms that allow for the discovery and development of innovative therapies. One of Innate Pharma SA's core competencies is the discovery and characterization of natural killer cells (NK cells), an important type of immune cell responsible for defending against cancer cells and viral infections. The company specializes in the development of NK cell-based immunotherapies aimed at mobilizing the immune system to fight cancer cells. Innate Pharma SA currently offers several products and therapies in various stages of clinical development. One important product is Monalizumab, a monoclonal antibody aimed at reducing immune suppression in tumors and promoting the activation of T cells and NK cells. Monalizumab is currently in a Phase III study for the treatment of head and neck squamous cell carcinomas. Another important product from Innate Pharma SA is IPH4102, a monoclonal antibody targeting CD47, a molecule overexpressed by cancer cells. IPH4102 has the potential to recognize and destroy cancer cells by promoting the engulfment of cancer cells by macrophages. The drug is currently in a Phase II study for the treatment of T-cell lymphomas. Innate Pharma SA also has a pipeline of promising NK cell-based immunotherapies in clinical development, including a bispecific antibody targeting CD16 and CD19, and a recombinant interleukin-15 protein that promotes the proliferation and activation of NK cells. Additionally, Innate Pharma SA has entered into a strategic partnership with AstraZeneca plc to advance the development and commercialization of Lumoxiti (Moxetumomab pasudotox), an FDA-approved antibody therapy used for the treatment of hairy cell leukemia. Innate Pharma SA primarily funds its business through private and public financing, including investments from venture capital firms and government research grants. The company has also established successful partnerships with other leading biopharmaceutical companies such as Bristol-Myers Squibb and Novo Nordisk to develop innovative immunoncology therapies. In summary, Innate Pharma SA's business model is based on the identification and development of novel immunoncology therapies, particularly NK cell-based immunotherapies. The company has an extensive portfolio of proprietary technologies and platforms that allow for the discovery and development of innovative therapies. Innate Pharma SA currently offers several products and therapies in various stages of clinical development, including Monalizumab, IPH4102, and other promising NK cell-based immunotherapies.
The expected revenue of Innate Pharma is 49.38 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Innate Pharma is -11.92 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Innate Pharma is currently -10.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Innate Pharma stock.
The price-to-sales ratio (P/S) of Innate Pharma is currently 2.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Innate Pharma stock.
The Eulerpool Quality Score for Innate Pharma is 1/10.
The ISIN of Innate Pharma is FR0010331421. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Innate Pharma is A0LCUJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Innate Pharma is IPH.PA. The ticker symbol is used to trade Innate Pharma shares on the stock exchange.
Innate Pharma stock
Innate Pharma Peer Group
Innate Pharma Ticker
Innate Pharma FIGI
All fundamentals and in-depth analysis of Innate Pharma
Our stock analysis for Innate Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innate Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.